pLatelEts And MigRaine iN patEnt foRamen Ovale

Status Completed

Clinical Trial Summary

Migraine is a common, chronic neurovascular disorder characterized by attacks of severe headache, autonomic nervous system dysfunction and, in some patients, aura, and disabling neurological symptoms. Worldwide, migraine prevalence is as high as 18% in the general population. Increased frequency of patent foramen ovale (PFO) in migraineurs was first reported in 1998 in a case-control study. Since then, others have described a 60% prevalence of PFO in patients suffering from migraine with aura. The presence of a right-to-left shunt (RLS) is thought to be a potent trigger of migraine attacks, although the mechanism is unknown. Moreover, PFO closure has correlated with improved migraine symptoms in several retrospective uncontrolled studies. The aim of this single-center, prospective study is to assess the impact of PFO closure on migraine attacks over time together with evaluation of potential predictive risk factors.

Clinical Trial Description

The Study will evaluate the results of approximately 100 subjects from a single center study registered in this trial. Subjects who experienced transient ischemic attack (TIA) or stroke with a clinical indication to PFO closure and symptomatic for migraine with/o aura are considered for a migraine score analysis at baseline before PFO closure and during the subsequent follow-up (FU) at 6 and 12-months, together with lab evaluation for platelet reactivity tests (P selectin, Thromboxane B2), Prostaglandin E1 and 2 (PGE1, PGE2), serotonin, cytokines and prostaglandin PGE1 urinary metabolite run under aspirin therapy. The research questions are as follows: Does the presence of a large PFO have any impact on migraine with aura? Do migraineurs with aura and PFO have higher biomarkers of platelet activation than control patients? and are they at higher risk of stroke and TIA recurrences based on high on clopidogrel platelet reactivity? What is the effect of PFO severity on monthly migraine frequency and aura frequency? What is the result of PFO closure in migraineur patients with PFO? Do Migraine with aura patients with large PFO have higher platelet activation and better migraine resolution after PFO closure? ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03521193
Study type	Interventional
Source	Centro Cardiologico Monzino
Contact
Status	Completed
Phase	N/A
Start date	February 15, 2018
Completion date	October 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02253004` - Induction of Migraine Aura With Cilostazol	Phase 0
Recruiting	`NCT02202486` - Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI	N/A
Completed	`NCT00123201` - Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache	Phase 2
Completed	`NCT04406649` - A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine	Phase 3
Completed	`NCT03874832` - A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects	Phase 1
Recruiting	`NCT05565001` - The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	N/A
Recruiting	`NCT05416476` - Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine	Phase 3
Active, not recruiting	`NCT02906085` - Endothelin-1 as a Potential Trigger of Migraine Aura	N/A
Recruiting	`NCT00893594` - Efficacy of Sumatriptan With Naprosyn in Migraine With Aura	N/A
Completed	`NCT01388699` - Migraine and Endothelial Dysfunction
Completed	`NCT00534560` - Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache	Phase 2
Terminated	`NCT04936061` - Transnasal Cooling for Migraine	N/A
Recruiting	`NCT05281770` - Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
Not yet recruiting	`NCT04063540` - Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura	Phase 2
Completed	`NCT03472417` - Partial Rebreathing in the Treatment of Migraine With Aura	N/A
Completed	`NCT00334178` - Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine	Phase 3
Recruiting	`NCT06051604` - Mi-Helper Transnasal Cooling for Acute Treatment of Migraine	N/A
Completed	`NCT03472378` - Can DFN-15 Terminate Migraine With Allodynia?	Phase 2
Recruiting	`NCT05211154` - Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine	Phase 4
Completed	`NCT02708797` - Brainstem Grey Matter and Cerebral Autoregulation in Migraine With Aura.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

pLatelEts And MigRaine iN patEnt foRamen Ovale — LEARNER

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms